Shots:
BMS has reported the topline P-III (ALOFT-IPF) trial data assessing admilparant (60 & 120mg, PO, BID) vs PBO for ≥52wks. in adults (n=~1,255; ≥40yrs.) with idiopathic pulmonary fibrosis (IPF)
Trial met its 1EP at 60mg showing improvement in FVC at Wk. 52, with 120mg also slowing the decline of FVC but was not statistically…
